BIOMAT Database Logo BIOMAT Database Logo

Myasthenia gravis-associated ryanodine receptor antibodies inhibit binding of ryanodine to sarcoplasmic reticulum. 1998

G O Skeie, and P K Lunde, and O M Sejersted, and A Mygland, and J A Aarli, and N E Gilhus
Department of Neurology, University of Bergen, Norway.

UI MeSH Term Description Entries
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D012433 Ryanodine A methylpyrrole-carboxylate from RYANIA that disrupts the RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL to modify CALCIUM release from SARCOPLASMIC RETICULUM resulting in alteration of MUSCLE CONTRACTION. It was previously used in INSECTICIDES. It is used experimentally in conjunction with THAPSIGARGIN and other inhibitors of CALCIUM ATPASE uptake of calcium into SARCOPLASMIC RETICULUM.
D012519 Sarcoplasmic Reticulum A network of tubules and sacs in the cytoplasm of SKELETAL MUSCLE FIBERS that assist with muscle contraction and relaxation by releasing and storing calcium ions. Reticulum, Sarcoplasmic,Reticulums, Sarcoplasmic,Sarcoplasmic Reticulums
D013945 Thymoma A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed) Carcinoma, Thymic,Carcinomas, Thymic,Thymic Carcinoma,Thymic Carcinomas,Thymomas
D013953 Thymus Neoplasms Tumors or cancer of the THYMUS GLAND. Cancer of Thymus,Thymus Cancer,Thymus Tumors,Cancer of the Thymus,Neoplasms, Thymic,Neoplasms, Thymus,Thymic Cancer,Thymic Neoplasms,Thymic Tumors,Cancer, Thymic,Cancer, Thymus,Cancers, Thymic,Cancers, Thymus,Neoplasm, Thymic,Neoplasm, Thymus,Thymic Cancers,Thymic Neoplasm,Thymic Tumor,Thymus Cancers,Thymus Neoplasm,Thymus Tumor,Tumor, Thymic,Tumor, Thymus,Tumors, Thymic,Tumors, Thymus
D018482 Muscle, Skeletal A subtype of striated muscle, attached by TENDONS to the SKELETON. Skeletal muscles are innervated and their movement can be consciously controlled. They are also called voluntary muscles. Anterior Tibial Muscle,Gastrocnemius Muscle,Muscle, Voluntary,Plantaris Muscle,Skeletal Muscle,Soleus Muscle,Muscle, Anterior Tibial,Muscle, Gastrocnemius,Muscle, Plantaris,Muscle, Soleus,Muscles, Skeletal,Muscles, Voluntary,Skeletal Muscles,Tibial Muscle, Anterior,Voluntary Muscle,Voluntary Muscles

Related Publications

G O Skeie, and P K Lunde, and O M Sejersted, and A Mygland, and J A Aarli, and N E Gilhus
Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis.
July 1994, Journal of neurology, neurosurgery, and psychiatry,
G O Skeie, and P K Lunde, and O M Sejersted, and A Mygland, and J A Aarli, and N E Gilhus
Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis.
January 1994, Autoimmunity,
G O Skeie, and P K Lunde, and O M Sejersted, and A Mygland, and J A Aarli, and N E Gilhus
Titin and ryanodine receptor antibodies in myasthenia gravis.
January 2006, Acta neurologica Scandinavica. Supplementum,
G O Skeie, and P K Lunde, and O M Sejersted, and A Mygland, and J A Aarli, and N E Gilhus
Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis.
May 2004, Neurology,
G O Skeie, and P K Lunde, and O M Sejersted, and A Mygland, and J A Aarli, and N E Gilhus
Ryanodine receptor channel of sarcoplasmic reticulum.
October 1988, Trends in neurosciences,
G O Skeie, and P K Lunde, and O M Sejersted, and A Mygland, and J A Aarli, and N E Gilhus
Direct binding of verapamil to the ryanodine receptor channel of sarcoplasmic reticulum.
August 1990, Biophysical journal,
G O Skeie, and P K Lunde, and O M Sejersted, and A Mygland, and J A Aarli, and N E Gilhus
Metabolic end products inhibit sarcoplasmic reticulum Ca2+ release and [3H]ryanodine binding.
May 1995, Journal of applied physiology (Bethesda, Md. : 1985),
G O Skeie, and P K Lunde, and O M Sejersted, and A Mygland, and J A Aarli, and N E Gilhus
Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features.
June 2007, European journal of neurology,
G O Skeie, and P K Lunde, and O M Sejersted, and A Mygland, and J A Aarli, and N E Gilhus
Binding of myasthenia gravis antibodies to different acetylcholine receptor preparations.
April 1982, Israel journal of medical sciences,
G O Skeie, and P K Lunde, and O M Sejersted, and A Mygland, and J A Aarli, and N E Gilhus
Myasthenia gravis: antibodies to acetylcholine receptor in ocular myasthenia gravis.
January 1981, Journal of neurology,
Copied contents to your clipboard!